Following in the footsteps of blockbuster drugs such as Ozempic and Wegovy—both powered by semaglutide—Mounjaro (approved for ...
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli Lilly, and more news to start your day.
today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers. Under this new ...
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
5don MSN
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...
Through Synapticure, patients will be able to use LillyDirect to find in-person Alzheimer’s specialists or to connect with ...
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...
Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback